JP2009527499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009527499A5 JP2009527499A5 JP2008555527A JP2008555527A JP2009527499A5 JP 2009527499 A5 JP2009527499 A5 JP 2009527499A5 JP 2008555527 A JP2008555527 A JP 2008555527A JP 2008555527 A JP2008555527 A JP 2008555527A JP 2009527499 A5 JP2009527499 A5 JP 2009527499A5
- Authority
- JP
- Japan
- Prior art keywords
- pen
- qrf
- sar
- peptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 83
- 235000001014 amino acid Nutrition 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 108010016626 Dipeptides Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 9
- -1 aromatic amino acid Chemical class 0.000 claims description 8
- YKVVSZDSPDUEMH-RXMQYKEDSA-N 2-[(3r)-3-amino-2-oxopiperidin-1-yl]acetic acid Chemical compound N[C@@H]1CCCN(CC(O)=O)C1=O YKVVSZDSPDUEMH-RXMQYKEDSA-N 0.000 claims description 6
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 150000003951 lactams Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229960001639 penicillamine Drugs 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 4
- 108010077895 Sarcosine Proteins 0.000 claims description 4
- 229940043230 sarcosine Drugs 0.000 claims description 4
- ZMCJOKMEFYSAOH-SCSAIBSYSA-N 2-[(3r)-3-amino-2-oxopyrrolidin-1-yl]acetic acid Chemical compound N[C@@H]1CCN(CC(O)=O)C1=O ZMCJOKMEFYSAOH-SCSAIBSYSA-N 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 9
- YKVVSZDSPDUEMH-UHFFFAOYSA-N 2-(3-amino-2-oxopiperidin-1-yl)acetic acid Chemical group NC1CCCN(CC(O)=O)C1=O YKVVSZDSPDUEMH-UHFFFAOYSA-N 0.000 claims 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 5
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 5
- 235000003704 aspartic acid Nutrition 0.000 claims 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 5
- JTCTZPXAQOMDEI-UHFFFAOYSA-N 2-(3-amino-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl)acetic acid Chemical group OC(=O)CN1C(=O)C(N)CCC2=CC=CC=C21 JTCTZPXAQOMDEI-UHFFFAOYSA-N 0.000 claims 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 4
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 4
- 235000013922 glutamic acid Nutrition 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 241000721454 Pemphigus Species 0.000 claims 3
- 201000001981 dermatomyositis Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 2
- XUSKZLBLGHBCLD-UHFFFAOYSA-N 2-(3-aminophenyl)acetic acid Chemical group NC1=CC=CC(CC(O)=O)=C1 XUSKZLBLGHBCLD-UHFFFAOYSA-N 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- HROBHVURICMOFT-ULOXDNNXSA-N chembl504968 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CC=CC=C1 HROBHVURICMOFT-ULOXDNNXSA-N 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 claims 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims 1
- CSEWAUGPAQPMDC-UHFFFAOYSA-N 2-(4-aminophenyl)acetic acid Chemical group NC1=CC=C(CC(O)=O)C=C1 CSEWAUGPAQPMDC-UHFFFAOYSA-N 0.000 claims 1
- YKVVSZDSPDUEMH-YFKPBYRVSA-N 2-[(3s)-3-amino-2-oxopiperidin-1-yl]acetic acid Chemical compound N[C@H]1CCCN(CC(O)=O)C1=O YKVVSZDSPDUEMH-YFKPBYRVSA-N 0.000 claims 1
- GSWYUZQBLVUEPH-UHFFFAOYSA-N 3-(azaniumylmethyl)benzoate Chemical group NCC1=CC=CC(C(O)=O)=C1 GSWYUZQBLVUEPH-UHFFFAOYSA-N 0.000 claims 1
- NIGWMJHCCYYCSF-QMMMGPOBSA-N 4-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-QMMMGPOBSA-N 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical group NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 claims 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 150000001510 aspartic acids Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 150000004652 butanoic acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- XFKSGNARKLOKSR-GVCIWFFJSA-N chembl451944 Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CC=CC=C1 XFKSGNARKLOKSR-GVCIWFFJSA-N 0.000 claims 1
- RNDLHDADENIYQB-PYKOPHRNSA-N chembl499790 Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)[C@H](C)O)C(C)C)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 RNDLHDADENIYQB-PYKOPHRNSA-N 0.000 claims 1
- NVLFUIQQQXPSCK-ULOXDNNXSA-N chembl500525 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CC=CC=C1 NVLFUIQQQXPSCK-ULOXDNNXSA-N 0.000 claims 1
- KZNISIFFYHJCFV-DCUVTQBESA-N chembl501035 Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CC=CC=C1 KZNISIFFYHJCFV-DCUVTQBESA-N 0.000 claims 1
- IQARFOIQUSLJBV-HFVQQTQISA-N chembl501558 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N1)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H]1NCCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O)=O)[C@@H](C)CC)[C@@H](C)CC)C1=CN=CN1 IQARFOIQUSLJBV-HFVQQTQISA-N 0.000 claims 1
- LRHRRCBDEMECGP-MHJZOWPKSA-N chembl503730 Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CC=CC=C1 LRHRRCBDEMECGP-MHJZOWPKSA-N 0.000 claims 1
- PPQQQQUDHBZTAW-ZUNNVFAGSA-N chembl510017 Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)C1=CC=CC=C1 PPQQQQUDHBZTAW-ZUNNVFAGSA-N 0.000 claims 1
- KGWSPAXUBOZHGD-UDZGLHSYSA-N chembl524509 Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CC=CC=C1 KGWSPAXUBOZHGD-UDZGLHSYSA-N 0.000 claims 1
- BAXZNYMLTXZPTP-ULOXDNNXSA-N chembl524711 Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CC=CC=C1 BAXZNYMLTXZPTP-ULOXDNNXSA-N 0.000 claims 1
- PPIIPSJYNJFJCC-RBZKBCOGSA-N chembl525060 Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CC=CC=C1 PPIIPSJYNJFJCC-RBZKBCOGSA-N 0.000 claims 1
- GOKZXJDBZOKFTE-PVLMKORCSA-N chembl526348 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C1=CN=CN1 GOKZXJDBZOKFTE-PVLMKORCSA-N 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 1
- 229960005156 digoxin Drugs 0.000 claims 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 150000002332 glycine derivatives Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 239000006249 magnetic particle Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 239000002077 nanosphere Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000002994 phenylalanines Chemical class 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000009163 protein therapy Methods 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 230000003582 thrombocytopenic effect Effects 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 150000002411 histidines Chemical class 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- MPVGCCAXXFLGIU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(prop-2-enoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 MPVGCCAXXFLGIU-IBGZPJMESA-N 0.000 description 1
- YIVBOSPUFNDYMF-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-(prop-2-enoxycarbonylamino)butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 YIVBOSPUFNDYMF-FQEVSTJZSA-N 0.000 description 1
- FBNFRRNBFASDKS-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-prop-2-enoxybutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 FBNFRRNBFASDKS-IBGZPJMESA-N 0.000 description 1
- RXLIOYNXBHZZBI-NRFANRHFSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-(prop-2-enoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 RXLIOYNXBHZZBI-NRFANRHFSA-N 0.000 description 1
- OJBNDXHENJDCBA-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-(prop-2-enoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 OJBNDXHENJDCBA-QFIPXVFZSA-N 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- 229930182818 D-methionine Natural products 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- WGNZRLMOMHJUSP-UHFFFAOYSA-N benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 WGNZRLMOMHJUSP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77485306P | 2006-02-17 | 2006-02-17 | |
| US80563406P | 2006-06-23 | 2006-06-23 | |
| PCT/US2007/062349 WO2007098420A2 (en) | 2006-02-17 | 2007-02-16 | Peptides that block the binding of igg to fcrn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009527499A JP2009527499A (ja) | 2009-07-30 |
| JP2009527499A5 true JP2009527499A5 (https=) | 2010-04-08 |
Family
ID=38291305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555527A Withdrawn JP2009527499A (ja) | 2006-02-17 | 2007-02-16 | ＩｇＧのＦｃＲＮへの結合をブロックするペプチド |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8101186B2 (https=) |
| EP (1) | EP1991572A2 (https=) |
| JP (1) | JP2009527499A (https=) |
| KR (1) | KR20080106432A (https=) |
| AU (1) | AU2007217042A1 (https=) |
| BR (1) | BRPI0707920A2 (https=) |
| CA (1) | CA2638867A1 (https=) |
| EA (1) | EA200870274A1 (https=) |
| IL (1) | IL193101A0 (https=) |
| ME (1) | MEP7408A (https=) |
| MX (1) | MX2008010327A (https=) |
| NO (1) | NO20083712L (https=) |
| RS (1) | RS20080362A (https=) |
| TR (2) | TR200807263A2 (https=) |
| TW (1) | TW200745163A (https=) |
| WO (1) | WO2007098420A2 (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2449918B1 (de) * | 2003-04-22 | 2013-07-10 | Trisa Holding AG | Bürstenkopf für eine Elektrozahnbürste |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
| MX2010001363A (es) * | 2007-08-09 | 2010-03-09 | Syntonix Pharmaceuticals Inc | Peptidos inmunomoduladores. |
| WO2010014909A1 (en) * | 2008-08-01 | 2010-02-04 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| WO2010141329A1 (en) | 2009-06-01 | 2010-12-09 | Medimmune, Llc | Molecules with extended half-lives and uses thereof |
| JP2013511554A (ja) * | 2009-11-23 | 2013-04-04 | パラティン テクノロジーズ，インコーポレイテッド | メラノコルチン−１受容体特異的線状ペプチド |
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| CN104011207B (zh) | 2011-10-31 | 2018-09-18 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
| SG10201805584YA (en) | 2012-02-24 | 2018-08-30 | Chugai Pharmaceutical Co Ltd | ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| ES2660912T3 (es) | 2013-03-15 | 2018-03-26 | Affibody Ab | Nuevos polipéptidos |
| WO2014205072A2 (en) | 2013-06-18 | 2014-12-24 | The Brigham And Women's Hospital, Inc. | FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF |
| GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| CN112142843B (zh) | 2013-12-24 | 2024-10-18 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| CN118440206A (zh) | 2014-04-07 | 2024-08-06 | 中外制药株式会社 | 免疫活化抗原结合分子 |
| EP3144388B1 (en) | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
| ES2743809T3 (es) | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| SI3193930T1 (sl) | 2014-09-17 | 2019-10-30 | Affibody Ab | Novi polipeptidi |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| JP6781712B2 (ja) * | 2014-12-22 | 2020-11-04 | コンシッリョ ナツィオナーレ デッレ リチェルケＣｏｎｓｉｇｌｉｏ Ｎａｚｉｏｎａｌｅ Ｄｅｌｌｅ Ｒｉｃｅｒｃｈｅ | 心臓へ治療用／診断用化合物を送達するための生成物 |
| MY188761A (en) | 2015-03-09 | 2021-12-29 | Argenx Bvba | Method of reducing serum levels of fc-containing agents using fcrn antagonists |
| ES2945313T3 (es) | 2015-04-17 | 2023-06-30 | Amgen Res Munich Gmbh | Construcciones de anticuerpos biespecificos para CDH3 y CD3 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| CN108368166B (zh) | 2015-12-28 | 2023-03-28 | 中外制药株式会社 | 提高含fc区多肽纯化效率的方法 |
| EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| CN106771251B (zh) * | 2017-01-10 | 2019-03-15 | 柏荣诊断产品（上海）有限公司 | 兼顾特异性和灵敏度的免疫球蛋白G4亚型IgG4检测试剂盒 |
| DK3661954T3 (da) | 2017-08-03 | 2022-04-19 | Amgen Inc | Interleukin-21-muteiner og fremgangsmåder til behandling |
| MA50077A (fr) | 2017-09-08 | 2020-07-15 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CN107903302B (zh) * | 2017-11-22 | 2021-05-14 | 韶远科技（上海)有限公司 | 一种γ-内酰胺桥联二肽类化合物的制备方法 |
| CN111615517B (zh) * | 2017-11-27 | 2024-01-09 | 香港大学 | Yeats抑制剂及其使用方法 |
| US12240875B2 (en) | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| CA3101462A1 (en) | 2018-06-08 | 2019-12-12 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
| JOP20210022A1 (ar) | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| WO2020227341A1 (en) * | 2019-05-06 | 2020-11-12 | 9 Meters Biopharma, Inc. | Compositions and methods for treating sjogren's syndrome |
| CN114126647A (zh) | 2019-06-07 | 2022-03-01 | 阿尔金克斯有限公司 | 适用于皮下施用的FcRn抑制剂的药物制剂 |
| CR20220049A (es) | 2019-07-10 | 2022-03-02 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a claudina-6 y usos de las mismas |
| EP3819007B1 (en) | 2019-11-11 | 2024-07-10 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
| EP4085144A4 (en) | 2019-12-19 | 2024-03-27 | The Trustees of The University of Pennsylvania | COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH AAXIA |
| BR112022013554A2 (pt) | 2020-01-08 | 2022-09-06 | argenx BV | Métodos para tratar distúrbios do pênfigo |
| EP4093771A1 (en) | 2020-01-22 | 2022-11-30 | Amgen Research (Munich) GmbH | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| IL325936A (en) * | 2020-01-22 | 2026-03-01 | Spark Therapeutics Inc | Compositions and methods for enhancing or improving transduction of gene therapy vectors and removing or reducing immunoglobulins |
| WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| US12312412B2 (en) | 2020-05-19 | 2025-05-27 | Amgen Inc. | MAGEB2 binding constructs |
| US20230220069A1 (en) | 2020-06-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| IL301926A (en) | 2020-11-06 | 2023-06-01 | Amgen Inc | Antigen binding domain with reduced clipping rate |
| EP4240767A1 (en) | 2020-11-06 | 2023-09-13 | Amgen Inc. | Polypeptide constructs binding to cd3 |
| AU2021374036A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
| US20250136704A1 (en) | 2020-11-10 | 2025-05-01 | Amgen Inc. | Methods for administering a bcmaxcd3 binding molecule |
| EP4274592A4 (en) * | 2021-01-11 | 2025-03-19 | The Trustees of The University of Pennsylvania | COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA |
| US20240309065A1 (en) | 2021-06-23 | 2024-09-19 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Short apoc-ii mimetic peptides and methods of use |
| WO2023109928A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海宝济药业有限公司 | 抗免疫球蛋白降解酶酶切的Fc变体 |
| US20250101104A1 (en) | 2022-01-26 | 2025-03-27 | Mabswitch Inc. | Bispecific molecule with tunable affinity to a targeted antigen |
| IL316418A (en) | 2022-05-05 | 2024-12-01 | Us Health | Short apolipoprotein E mimetic peptides and methods of use |
| CA3258000A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| GB202318512D0 (en) * | 2023-12-04 | 2024-01-17 | argenx BV | Methods of determining potency |
| US20260092096A1 (en) | 2024-05-14 | 2026-04-02 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
| WO2026035730A1 (en) | 2024-08-06 | 2026-02-12 | Covant Therapeutics Operating, Inc. | Cyclic peptide modulators of fcrn and uses thereof |
| WO2026055212A1 (en) | 2024-09-03 | 2026-03-12 | Covant Therapeutics Operating, Inc. | Allosteric modulators of fcrn and uses thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5888512A (en) * | 1987-01-30 | 1999-03-30 | Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte activity regulation by HLA peptides |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5677440A (en) | 1990-07-16 | 1997-10-14 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates |
| US5492821A (en) | 1990-11-14 | 1996-02-20 | Cargill, Inc. | Stabilized polyacrylic saccharide protein conjugates |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| US5623053A (en) | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| US5449761A (en) | 1993-09-28 | 1995-09-12 | Cytogen Corporation | Metal-binding targeted polypeptide constructs |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CN1214080A (zh) | 1995-09-26 | 1999-04-14 | 华盛顿州大学 | Rfhv/kshv亚族疱疹病毒的糖蛋白b |
| US7141676B1 (en) | 1996-02-08 | 2006-11-28 | University Of Washington | Water soluble multi-biotin-containing compounds |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US6214795B1 (en) * | 1996-11-12 | 2001-04-10 | Praecis Pharmaceuticals, Inc. | Peptide compounds useful for modulating FGF receptor activity |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
| US6472506B1 (en) | 1997-01-21 | 2002-10-29 | Aventis Pasteur S.A. | Polysaccharide-peptide-conjugates |
| US6281331B1 (en) | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6197526B1 (en) | 1999-01-04 | 2001-03-06 | Dyax Corp. | Polypeptides for binding human factor VIII and fragments of human factor VIII |
| US7473528B2 (en) | 1999-01-06 | 2009-01-06 | Genenews Inc. | Method for the detection of Chagas disease related gene transcripts in blood |
| US20040241727A1 (en) | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of schizophrenia related gene transcripts in blood |
| US6469136B1 (en) | 1999-07-07 | 2002-10-22 | Trimeris, Inc. | Methods and composition for peptide synthesis |
| RU2269354C2 (ru) * | 1999-09-28 | 2006-02-10 | Байер Корпорейшн | Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения |
| AU5943201A (en) | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| JP2002214374A (ja) | 2001-01-15 | 2002-07-31 | Agilent Technologies Japan Ltd | 位置決め装置及び位置決め方法 |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| WO2004043403A2 (en) | 2002-11-13 | 2004-05-27 | The Uab Research Foundation | Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use |
| WO2005035732A2 (en) | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
| CA2522690A1 (en) | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition of drug binding to serum albumin |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2004108885A2 (en) | 2003-05-06 | 2004-12-16 | Syntonix Pharmaceuticals, Inc. | Fc chimeric proteins with anti-hiv drugs |
| JP2007501847A (ja) | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| US7232805B2 (en) | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
| CA2552788C (en) * | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| DE102004031579B4 (de) * | 2004-06-29 | 2012-12-27 | Forschungsverbund Berlin E.V. | Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen, diese umfassendes Nukleinsäuremolekül, Vektor, Wirtszelle, gegen diese gerichtetes Erkennungsmolekül, diese enthaltende pharmazeutische Zusammensetzung, diese enthaltender Kit und deren Verwendung |
| EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| MX2010001363A (es) | 2007-08-09 | 2010-03-09 | Syntonix Pharmaceuticals Inc | Peptidos inmunomoduladores. |
| WO2010014909A1 (en) | 2008-08-01 | 2010-02-04 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
-
2007
- 2007-02-15 TW TW096105711A patent/TW200745163A/zh unknown
- 2007-02-16 US US11/676,148 patent/US8101186B2/en not_active Expired - Fee Related
- 2007-02-16 ME MEP7408 patent/MEP7408A/xx unknown
- 2007-02-16 WO PCT/US2007/062349 patent/WO2007098420A2/en not_active Ceased
- 2007-02-16 JP JP2008555527A patent/JP2009527499A/ja not_active Withdrawn
- 2007-02-16 KR KR20087022493A patent/KR20080106432A/ko not_active Withdrawn
- 2007-02-16 BR BRPI0707920-6A patent/BRPI0707920A2/pt not_active IP Right Cessation
- 2007-02-16 CA CA 2638867 patent/CA2638867A1/en not_active Abandoned
- 2007-02-16 TR TR200807263A patent/TR200807263A2/xx unknown
- 2007-02-16 AU AU2007217042A patent/AU2007217042A1/en not_active Abandoned
- 2007-02-16 RS RSP20080362 patent/RS20080362A/sr unknown
- 2007-02-16 EA EA200870274A patent/EA200870274A1/ru unknown
- 2007-02-16 MX MX2008010327A patent/MX2008010327A/es not_active Application Discontinuation
- 2007-02-16 EP EP07757148A patent/EP1991572A2/en not_active Withdrawn
- 2007-02-16 TR TR200807263T patent/TR200807263T1/xx unknown
-
2008
- 2008-07-29 IL IL193101A patent/IL193101A0/en unknown
- 2008-08-28 NO NO20083712A patent/NO20083712L/no not_active Application Discontinuation
-
2009
- 2009-12-18 US US12/641,844 patent/US9012603B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009527499A5 (https=) | ||
| US6022523A (en) | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | |
| BR112020010410A2 (pt) | análogos de incretina e o uso dos mesmos | |
| CA2717427A1 (en) | Bombesin analog peptide antagonist conjugates | |
| BR112016008996B1 (pt) | Ligante peptídico específico para calicreína plasmática e composição farmacêutica | |
| CA2089747A1 (en) | Cyclopeptides, a method of preparing them, and their use as drugs | |
| TW200911289A (en) | Immunomodulatory peptides | |
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| CN116018349A (zh) | 抗感染的双环肽配体 | |
| CN101107264A (zh) | C5a受体拮抗剂 | |
| CA3206846A1 (en) | Anti-infective bicyclic peptide ligands | |
| CA2192787A1 (en) | Pth or pthrp antagonists | |
| JPH04500666A (ja) | ペプチド化合物 | |
| JP2949129B2 (ja) | 胃腸運動刺激活性を有するモチリン類似ポリペプチド | |
| CN119930814A (zh) | 针对vegf的d-肽化合物 | |
| Inman et al. | Synthesis of N. alpha.-(tert-butoxycarbonyl)-N. epsilon.-[N-(bromoacetyl)-. beta.-alanyl]-L-lysine: Its use in peptide synthesis for placing a bromoacetyl cross-linking function at any desired sequence position | |
| CN101379077A (zh) | 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体 | |
| AU2016261299B2 (en) | Influenza virus neutralizing peptidomimetic compounds | |
| Masuda et al. | Concise site-specific synthesis of DTPA–peptide conjugates: Application to imaging probes for the chemokine receptor CXCR4 | |
| CN117120459A (zh) | 抗感染双环肽配体 | |
| JPH0687891A (ja) | ブラジキニン−アンタゴニスト活性を有するペプチド化合物 | |
| JPH06509571A (ja) | タキキニン拮抗薬としての環状ヘキサペプチドの製法およびその薬学的化合物 | |
| JP2024509996A (ja) | Ｔｒｅｍ２に特異的な二環式ペプチドリガンド | |
| HK40069562B (zh) | 钙敏感受体激动剂化合物及其应用 | |
| HK1027580A (en) | Radiolabeled platelet gpiib/iiia receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |